Abstract
There has been much progress in our understanding of transthyretin (TTR)-related amyloidosis including familial amyloidotic polyneuropathy (FAP), senile systemic amyloidosis and its related disorders from many clinical and experimental aspects. FAP is an inherited severe systemic amyloidosis caused by mutated TTR, and characterized by amyloid deposition mainly in the peripheral nervous system and the heart. Liver transplantation is the only available treatment for the disease. FAP is now recognized not to be a rare disease, and to have many variations based on genetical and biochemical variations of TTR. This chapter covers the recent advances in the clinical and pathological aspects of, and therapeutic approaches to FAP, and the trend as to the molecular pathogenesis of TTR.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adams D, Samuel D, Goulon-Goeau C, Nakazato M, Costa PM, Feray C, Planté V, Ducot B, Ichai P, Lacroix C, Metral S, Bismuth H, Said G (2000) The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 123:1495–1504.
Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW (2004) Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem 47:355–374
Afolabi I, Hamidi Asl K, Nakamura M, Jacobs P, Hendrie H, Benson MD (2000) Transthyretin isoleucine-122 mutation in African and American blacks. Amyloid 7:121–125
Alhamadsheh MM, Connelly S, Cho A, Reixach N, Evan T, Powers ET, Pan DW, Wilson IA, Kelly JF, Graef IA (2011) Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Sci Transl Med 3:97ra81
Almeida MR, Alves IL, Terazaki H, Ando Y, Saraiva MJ (2000) Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and TTR T119M. Biochem Biophys Res Commun 270:1024–1028
Almeida MR, Macedo B, Cardoso I, Alves I, Valencia G, Arsequell G, Planas A, Saraiva MJ (2004) Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem J 381:351–356
Alves IL, Altland K, Almeida MR, Winter P, Saraiva MJ (1997) Screening and biochemical characterization of transthyretin variants in the Portuguese population. Hum Mutat 9:226–233
Ancsin JB (2003) Amyloidogenesis: historical and modern observations point to heparan sulfate proteoglycans as a major culprit. Amyloid 10:67–79
Andersson K, Olofsson A, Nielsen EH, Svehag SE, Lundgren E (2002) Only amyloidogenic intermediates of transthyretin induce apoptosis. Biochem Biophys Res Commun 294:309–314
Ando Y (2005) Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP). Med Mol Morphol 38:142–154
Ando Y (2010) FAP is a candidate disease in patients with undetermined polyneuropathy. Intern Med 49:1841–1842
Ando Y, Ueda M (2008) Novel methods for detecting amyloidogenic proteins in transthyretin related amyloidosis. Front Biosci 13:5548–5558
Ando Y, Yi S, Nakagawa T, Ikegawa S, Hirota M, Miyazaki A, Araki S (1991) Disturbed metabolism of glucose and related hormones in familial amyloidotic polyneuropathy: hypersensitivities of the autonomic nervous system and therapeutic prevention. J Auton Nerv Syst 35:63–70
Ando Y, Tanaka Y, Nakazato M, Ericzon BG, Yamashita T, Tashima K, Sakashita N, Suga M, Uchino M, Ando M (1995) Change in variant transthyretin levels in patients with familial amyloidotic polyneuropathy type I following liver transplantation. Biochem Biophys Res Commun 211:354–358
Ando Y, Yamashita T, Nakamura M, Tanaka Y, Hashimoto M, Tashima K, Suhr O, Uemura Y, Obayashi K, Terazaki H, Suga M, Uchino M, Ando M (1997) Down regulation of a harmful variant protein by replacement of its normal protein. Biochim Biophys Acta 1362:39–46
Ando Y, Terazaki H, Nakamura M, Ando E, Haraoka K, Yamashita T, Ueda M, Okabe H, Sasaki Y, Tanihara H, Uchino M, Inomata Y (2004) A different amyloid formation mechanism: de novo oculoleptomeningeal amyloid deposits after liver transplantation. Transplantation 77:345–349
Ando Y, Nakamura M, Araki S (2005) Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 62:1057–1062
Andrade C (1952) A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 75:408–427
Araki S, Ando Y (2010) Transthyretin-related familial amyloidotic polyneuropathy. Progress in Kumamoto, Japan (1967–2010). Proc Jpn Acad Ser B 86:694–706
Araki S, Mawatari S, Ohta M, Nakajima A, Kuroiwa Y (1968) Polyneuritic amyloidosis in a Japanese family. Arch Neurol 18:593–602
Armen RS, DeMarco ML, Alonso DO, Daggett V (2004) Pauling and Corey’s alpha-pleated sheet structure may define the prefibrillar amyloidogenic intermediate in amyloid disease. Proc Natl Acad Sci USA 101:11622–11627
Banerjee A, Bairagya HR, Mukhopadhyay BP, Nandi TK, Bera AK (2010) Structural insight to mutated Y116S transthyretin by molecular dynamics simulation. Indian J Biochem Biophys 47:197–202
Barouch FC, Benson MD, Mukai S (2004) Isolated vitreoretinal amyloidosis in the absence of transthyretin mutations. Arch Ophthalmol 122:123–125
Baures PW, Peterson SA, Kelly JW (1998) Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg Med Chem 6:1389–1401
Baures PW, Oza VB, Peterson SA, Kelly JW (1999) Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. Bioorg Med Chem 7:1339–1347
Benson MD, Cohen AS (1977) Generalized amyloid in a family of Swedish origin. A study of 426 family members in seven generations of a new kinship with neuropathy, nephropathy, and central nervous system involvement. Ann Intern Med 86:419–424
Benson MD, Wallace MR, Tejada E, Baumann H, Page B (1987) Hereditary amyloidosis: description of a new american kindred with late onset cardiomyopathy. Arthritis Rheum 30:195–200
Benson MD, Kluve-Beckerman B, Liepniesks JJ, Murrell JR, Hanes D, Uemichi T (1996) Metabolism of amyloid proteins. Ciba Found Symp 199:104–113
Benson MD, Kluve-Beckerman B, Zeldenrust SR, Siesky AM, Bodenmiller DM, Showalter AD, Sloop KW (2006) Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 33:609–618
Benson MD, Kincaid JC (2007) The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36:411–423
Benson MD, Smith RA, Hung G, Kluve-Beckerman B, Showalter AD, Sloop KW, Monia BP (2010) Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment. Amyloid 17:43–49
Berg I, Thor S, Hammarström P (2009) Modeling familial amyloidotic polyneuropathy (transthyretin V30M) in Drosophila melanogaster. Neurodegener Dis 6:127–138
Biolo A, Ramamurthy S, Connors LH, O’Hara CJ, Meier-Ewert HK, Soo Hoo PT, Sawyer DB, Seldin DS, Sam F (2008) Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition. Circ Heart Fail 1:249–257
Bittencourt PL, Couto CA, Leitão MC, Siqueira SA, Farias AQ, Massarolo PCB, Mies S (2002) No evidence of de novo amyloidosis in recipients of domino liver transplantation: 12 to 40 (mean 24) month follow-up. Amyloid 9:194–196
Blake CCF, Geisow MJ, Swan ID, Rérat C, Rérat B (1974) Structure of human plasma prealbumin at 2–5 Å resolution: a preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding. J Mol Biol 88:1–12
Blake CC, Oatley SJ (1977) Protein-DNA and protein-hormone interactions in prealbumin: a model of the thyroid hormone nuclear receptor? Nature 268:115–120
Blake C, Serpell L (1996) Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous beta-sheet helix. Structure 4:989–998
Blake CCF, Geisow MJ, Oatley SJ, Rérat B, Rérat C (1978) Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinementat 1.8 Å. J Mol Bio 121:339–356
Blevins G, Macaulay R, Harder S, Fladeland D, Yamashita T, Yazaki M, Hamidi Asl K, Benson MD, Donat JR (2003) Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His. Neurology 60:1625–1630
Bourgault S, Solomon JP, Reixach N, Kelly JW (2011) Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion. Biochemistry 50:1001–1015
Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416:507–511
Buxbaum JN (2009) Animal models of human amyloidoses: are transgenic mice worth the time and trouble? FEBS Lett 583:2663–2673
Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E, Roberts AR, Bartfai T (2008) Transthyretin protects Alzheimer’s mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci USA 105:2681–2686
Cardoso I, Goldsbury CS, Müller SA, Olivieri V, Wirtz S, Damas AM, Aebi U, Saraiva MJ (2002) Transthyretin fibrillogenesis entails the assembly of monomers, a molecular model for in vitro assembled transthyretin amyloid-like fibrils. J Mol Biol 317:683–685
Cardoso I, Martins D, Tania Ribeiro T, Merlini G, Saraiva MJ (2010) Synergy of combined doxycycline/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med 8:74–84
Cavallaro T, Martone RL, Dwork AJ, Schon EA, Herbert J (1990) The retinal pigment epithelium is the unique site of transthyretin synthesis in the rat eye. Invest Ophthalmol Vis Sci 31:497–501
Choi S, Reixach N, Connelly S, Johnson SM, Wilson IA, Kelly JW (2010) A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity. J Am Chem Soc 132:1359–1370
Chung CM, Connors LH, Benson MD, Walsh MT (2001) Biophysical analysis of normal transthyretin: implications for fibril formation in senile systemic amyloidosis. Amyloid 8:75–83
Coelho T, Carvalho M, Saraiva MJ, Alvas I, Almedia MR, Costa PP (1993) Familial amyloidotic polyneuropathy and other transthyretin related disorders. Proceedings of the Second International Symposium, Skelleftea, Sweden, 1992. J Rheumatol 20:179
Coelho T, Sousa A, Lourenço E, Ramalheira J (1994) A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected. Med Genet 31:293–299
Coimbra A, Andrade C (1971) Familial amyloid polyneuropathy: an electron microscope study of the peripheral nerve in five cases. II. Nerve fibre changes. Brain 94:207–212
Colon W, Kelly JW (1992) Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31:8654–8660
Connelly S, Choi S, Johnson SM, Kelly JW, Wilson IA (2010) Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol 20:54–62
Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE (2003) Tabulation of human transthyretin (TTR) variants. Amyloid 10:160–184
Cornwell GG, Murdoch WL, Kyle RA, Westermark P, Pitkänen P (1983) Frequency and distribution of senile cardiovascular amyloid: a clinicopathologic correlation. Am J Med 75:618–623
Costa PP, Figueira AS, Bravo FR (1978) Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci USA 75:4499–4503
da Costa G, Gomes RA, Guerreiro A, Mateus É, Monteiro E, Barroso E, Coelho AV, Freire AP, Cordeiro C (2011) Beyond genetic factors in familial amyloidotic polyneuropathy: protein glycation and the loss of fibrinogen’s chaperone activity. PLoS One 6:e24850
Dardiotis E, Koutsou P, Zamba-Papanicolaou E, Vonta I, Hadjivassiliou M, Hadjigeorgiou G, Cariolou M, Christodoulou K, Kyriakides T (2009) Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met. J Neurol Sci 284:158–162
Di Bella G, Minutoli F, Mazzeo A, Vita G, Oreto G, Carerj S, Anfuso C, Russo M, Gaeta M (2010) MRI of cardiac involvement in transthyretin familial amyloid polyneuropathy. Am J Roentgenol 195:394–399
Do Amaral B, Coelho T, Sousa A, Guimarães A (2009) Usefulness of labial salivary gland biopsy in familial amyloid polyneuropathy Portuguese type. Amyloid 16:232–238
Du J, Murphy RM (2010) Characterization of the interaction of β-amyloid with transthyretin monomers and tetramers. Biochemistry 49:8276–8289
Dubový P, Klusáková I, Svíženská I (2002) A quantitative immunohistochemical study of the endoneurium in the rat dorsal and ventral spinal roots. Histochem Cell Biol 117:473–480
Dwulet FE, Benson MD (1984) Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial polyneuropathy of Swedish origin. Proc Natl Acad Sci USA 81:694–698
Dwulet FE, Benson MD (1986) Characterization of prealbumin variant associated with familial amyloidotic polyneuropathy type II (Indiana/Swiss). J Clin Invest 78:880–886
Dyck PJ, Lambert EH (1969) Compound action potential, quantitative histologic and teased-fiber, and electron microscopic studies of sural nerve biopsies. Arch Neurol 20:490–507
El-Salhy M, Suhr O, Stenling R, Wilander E, Grimelius L (1994) Impact of familial amyloid associated polyneuropathy on duodenal endcrine cells. Gut 35:1413–1418
Eneqvist T, Andersson K, Olofsson A, Lundgren E, Sauer-Eriksson AE (2000) The beta-slip: a novel concept in transthyretin amyloidosis. Mol Cell 6:1207–1218
Episkopou V, Maeda S, Nishiguchi S, Shimada K, Gaitanaris GA, Gottesman ME, Robertson EJ (1993) Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc Natl Acad Sci USA 90:2375–2379
Falls HF, Jackson J, Carey JH, Rukavina JG, Block WD (1955) Ocular manifestations of hereditary primary systemic amyloidosis. Arch Ophthalmol 54:660–664
Ferrao-Gonzales AD, Palmieri L, Valory M, Silva JL, Lashuel H, Kelly JW, Foguel D (2003) Hydration and packing are crucial to amyloidogenesis as revealed by pressure studies on transthyretin variants that either protect or worsen amyloid disease. J Mol Biol 328:963–974
Ferreira N, Cardoso I, Domingues MR, Vitorino R, Bastos M, Bai G, Maria Saraiva J, Almeida MR (2009) Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett 583:3569–3576
Fiori MG, Salvi F, Plasmati R, Tessari F, Bianchi R, Tassinari CA (1994) Amyloid deposits inside myocardial fibers in transthyretin-Met30 familial amyloidotic polyneuropathy. A histological and biochemical study. Cardiology 85:145–153
Fleming CE, Saraiva MJ, Sousa MM (2007) Transthyretin enhances nerve regeneration. J Neurochem 103:831–839
Foguel D, Suarez MC, Ferrão-Gonzales AD, Porto TC, Palmieri L, Einsiedler CM, Andrade LR, Lashuel HA, Lansbury PT, Kelly JW, Silva JL (2003) Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities. Proc Natl Acad Sci USA 100:9831–9836
Foss TR, Kelker MS, Wiseman RL, Wilson IA, Kelly JW (2005) Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis. J Mol Biol 347:841–854
Fuchs U, Zittermann A, Suhr O, Holmgren G, Tenderich G, Minami K, Koerfer R (2005) Heart transplantation in a 68-year-old patient with senile systemic amyloidosis. Am J Transplant 5:1159–1162
Gallo G, Wisniewski T, Choi-Miura N-H, Ghiso J, Frangione B (1994) Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol 145:526–530
Gambetti P, Russo C (1998) Human brain amyloidosis. Nephrol Dial Transplant 13:33–40
Gasperini RJ, Hou X, Parkington H, Coleman H, Klaver DW, Vincent AJ, Foa LC, Small DH,(2011) TRPM8 and Nav1.8 sodium channels are required for transthyretin-induced calcium influx in growth cones of small-diameter TrkA-positive sensory neurons. Mol Neurodegener 6:19
Goebel HH, Seddigh S, Hopf HC, Uemichi T, Benson MD, McKusick VA (1997) A European family with histidine 58 transthyretin mutation in familial amyloid polyneuropathy. Neuromuscul Disord 7:229–230
Goren H, Steinberg MC, Farboody GH (1980) Familial oculoleptomeningeal amyloidosis. Brain 103:473–495
Greene MJ, Sam F, Soo Hoo PT, Patel RS, Seldin DC, Connors LH (2011) Evidence for a functional role of the molecular chaperone clusterin in amyloidotic cardiomyopathy. Am J Pathol 178:61–68
Groenning M, Campos RI, Fagerberg C, Rasmussen AA, Eriksen UH, Powers ET, Hammarström P (2011) Thermodynamic stability and denaturation kinetics of a benign natural transthyretin mutant identified in a Danish kindred. Amyloid 18:35–46
Gustavsson A, Engström U, Westermark P (1991) Normal transthyretin and synthetic transthyretin fragments form amyloid-like fibrils in vitro. Biochem Biophys Res Commun 175:1159–1164
Hagiwara K, Ochi H, Suzuki S, Shimizu Y, Tokuda T, Murai H, Shigeto H, Ohyagi Y, Iwata M, Iwaki T, Kira J (2009) Highly selective leptomeningeal amyloidosis with transthyretin variant Ala25Thr. Neurology 72:1358–1360
Hamilton JA, Benson MD (2001) Transthyretin: a review from a structural perspective. Cell Mol Life Sci 58:1491–1521
Hamilton JA, Steinrauf LK, Braden BC, Liepnieks J, Benson MD, Holmgren G, Sandgren O, Steen L (1993) The X-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30®Met variant to 1.7-Å resolution. J Biol Chem 268:2416–2424
Hammarström P, Schneider F, Kelly JW (2001) Trans-suppression of misfolding in an amyloid disease. Science 293:2459–2462
Hammarström P, Wiseman RL, Powers ET, Kelly JW (2003a) Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299:713–716
Hammarström P, Sekijima Y, White JT, Wiseman RL, Lim A, Costello CE, Altland K, Garzuly F, Budka H, Kelly JW (2003b) D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry 42:6656–6663
Hanyu N, Ikeda S, Nakadai A, Yanagisawa, N, Powell HC (1989) Peripheral nerve pathological findings in familial amyloid polyneuropathy: a correlative study of proximal sciatic nerve and sural nerve lesions. Ann Neurol 25:340–350
Hanyu N, Shimizu T, Yamauchi K, Okumura N, Hidaka H (2009) Characterization of cysteine and homocysteine bound to human serum transthyretin. Clin Chim Acta 403:70–75
Harats N, Robert M, Worth RM, Benson MD (1989) Hereditary amyloidosis: evidence against early amyloid deposition. Arthritis Rheum 32:1474–1476
Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellié C, Planté-Bordeneuve V (2008) Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 15:181–186
Herbert J, Wilcox JN, Pham KT, Fremeau RT Jr, Zeviani M, Dwork A, Soprano DR, Makover A, Goodman DS, Zimmerman EA, Roberts JL, Schon EA (1986) Transthyretin: a choroid plexus-specific transport protein in human brain. Neurology 36:900–911
Herlenius G, Wilczek HE, Larsson M, Ericzon B-G (2004) Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the familial amyloidotic polyneuropathy world transplant registry. Transplantation 77:64–71
Hofer PA, Anderson R (1975) Postmortem findings in primary familial amyloidosis with polyneuropathy. Acta Pathol Microbiol Scand A 83:309–322
Holmgren G, Holmberg E, Lindström A, Lindström E, Nordenson I, Sandgren O, Steen L, Svensson B, Lundgren E, von Gabain A (1988) Diagnosis of familial amyloidotic polyneuropathy in Sweden by RFLP analysis. Clin Genet 33:176–180
Holmgren G, Steen L, Ekstedt J, Groth C-G, Ericzon B-G, Eriksson S, Andersen O, Karlberg I, Nordén G, Nakazato M, Hawkins P, Richardson S, Pepys M (1991) Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 40:242–246
Holmgren G, Bergström S, Drugge U, Lundgren E, Nording-Sikström C, Sandgren O, Steen L (1992) Homozygosity for the transthyretin-Met30-gene in seven individuals with familial amyloidosis with polyneuropathy detected by restriction enzyme analysis of amplified genomic DNA sequences. Clin Genet 41:39–41
Holmgren G, Steen L, Suhr O, Ericzon B-G, Groth C-G, Andersen O, Wallin BG, Seymour A, Richardson S, Hawkins PN, Pepys MB (1993) Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 342:1113–1116
Holmgren G, Costa PMP, Andersson C, Asplund K, Steen L, Beckman L, Nylander P-O, Teixeira A, Saraiva MJM, Costa PP (1994) Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet 31:351–354
Hörnberg A, Eneqvist T, Olofsson A, Lundgren E, Sauer-Eriksson AE (2000) A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. J Mol Biol 302:649–669
Hörnsten R, Wiklund U, Olofsson B-O, Jensen SM, Suhr OB (2004) Liver transplantation does not prevent the development of life-threatening arrhythmia in familial amyloidotic polyneuropathy, Portuguese-type (ATTR Val30Met) patients. Transplantation 78:112–116
Hou X, Richardson SJ, Aguilar MI, Small DH (2005) Binding of amyloidogenic transthyretin to the plasma membrane alters membrane fluidity and induces neurotoxicity. Biochemistry 44:11618–11627
Hou X, Parkington HC, Coleman HA, Mechler A, Martin LL, Aguilar M-I, Small DH (2007) Transthyretin oligomers induce calcium influx via voltage-gated calcium channels. J Neurochem 100:446–457
Hund E, Linke RP, Willig F, Grau A (2001) Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment. Neurology 56:431–435
Hurshman Babbes AR, White JT, Powers ET, Kelly JW (2004) Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 43:7365–7381
Hurshman Babbes AR, Powers ET, Kelly JW (2008) Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry 47:6969–6984
Huttunen HJ, Fages C, Rauvala H (1999) Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 274:19919–19924
Hyung S-J, Deroo S, Robinson CV (2010) Retinol and retinol-binding protein stabilize transthyretin via formation of retinol transport complex. ACS Chem Biol 5:1137–1146
Ihse E, Suhr OB, Hellman U, Westermark P (2011) Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis. J Mol Med (Berl.) 89:171–180
Ikeda S (2004) Cardiac amyloidosis: heterogenous pathogenic backgrounds. Intern Med 43:1107–1114
Ikeda S, Hanyu N, Hongo M, Yoshioka J, Oguchi H, Yanagisawa N, Kobayashi T, Tsukagoshi H, Ito N, Yokota T (1987) Hereditary generalized amyloidosis with polyneuropathy, clinicopathological study of 65 Japanese patients. Brain 110:315–337
Ikeda S, Nakazato M, Ando Y, Sobue G (2002) Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 58:1001–1007
Ikeda S, Takei Y, Hashikura Y (2003) Liver transplantation as treatment for neurological disorders. Expert Rev Neurother 3:547–555
Ingenbleek K, Young V (1994) Transthyretin (prealbumin) in health and disease: nutritional implications. Annu Rev Nutr 14:495–533
Inoue S, Kuroiwa M, Saraiva MJ, Guimarães A, Kisilevsky R (1998) Ultrastructure of familial amyloid polyneuropathy amyloid fibrils: examination with high-resolution electron microscopy. J Struct Biol 124:1–12
Inoue S, Ohta M, Li Z, Zhao G, Takaoka Y, Sakashita N, Miyakawa K, Takada K, Tei H, Suzuki M, Masuoka M, Sakaki Y, Takahashi K, Yamamura K (2008) Specific pathogen free conditions prevent transthyretin amyloidosis in mouse models. Transgenic Res 17:817–826
Inouye H, Domingues FS, Damas AM, Saraiva MJ, Lundgren E, Sandgren O, Kirschner DA (1998) Analysis of x-ray diffraction patterns from amyloid of biopsied vitreous humor and kidney of transthyretin (TTR) Met30 familial amyloidotic polyneuropathy (FAP) patients: axially arrayed TTR monomers constitute the protofilament. Amyloid 5:163–174
Iozzo RV, Cohen IR, Grassel S, Murdoch AD (1994) The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 302:625–639
Izumoto S, Younger D, Hays AP, Martone RL, Smith RT, Herbert J (1992) Familial amyloidotic polyneuropathy presenting with carpal tunnel syndrome and a new transthyretin mutation, asparagine 70. Neurology 42:2094–2102
Jacobsson B, Collins VP, Grimelius L, Pettersson T, Sandstedt B, Carlström A (1989) Transthyretin immunoreactivity in human and porcine liver, choroid plexus, and pancreatic islets. J Histochem Cytochem 37:31–37
Jacobson DR, McFarlin DE, Kane I, Buxbaum JN (1992) Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement. Hum Genet 89:353–356
Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN,(1997) Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 336:466–473
Jacobson D, Tagoe C, Schwartzbard A, Shah A, Koziol J, Buxbaum J (2011) Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African-American men. Am J Cardiol 108:440–444
Jarrett JT, Lansbury PT Jr (1993) Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer’s disease and scrapie? Cell 73:1055–1058
Jiang X, Smith CS, Petrassi HM, Hammarström P, White JT, Sacchettini JC, Kelly JW (2001) An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry 40:11442–11452
Jinno Y, Matsumoto T, Kamel T, Kondoh T, Maeda S, Araki S, Shimada K, Niikawa N (1986) Localization of the human prealbumin gene to 18p11.1-q12.3 by gene dose effect study of southern blot hybridization. Jpn J Hum Genet 31:243–248
Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW (2005) Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res 38:911–921
Johnson SM, Connelly S, Wilson IA, Kelly JW (2008a) Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. J Med Chem 51:260–270
Johnson SM, Connelly S, Wilson IA, Kelly JW (2008b) Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J Med Chem 51:6348–6358
Johnson SM, Connelly S, Wilson IA, Kelly JW (2009) Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J Med Chem 52:1115–1125
Jono H, Anno T, Motoyama K, Misumi Y, Tasaki M, Toshinori Oshima T, Mori Y, Mizuguchi M, Ueda M, Shono M, Obayashi K, Arima H, Ando Y (2011) Cyclodextrin, a novel therapeutic tool for suppressing amyloidogenic transthyretin misfolding in transthyretin-related amyloidosis. Biochem J 437:35–42
Kanda Y, Goodman DS, Canfield RE, Morgans FJ (1974) The amino acid sequence of human plasma prealbumin. Biol Chem 249:6796–6806
Kassem NA, Deane R, Segal MB, Preston JE (2006) Role of transthyretin in thyroxine transfer from cerebrospinal fluid to brain and choroid plexus. Am J Physiol Regul Integr Comp Physiol 291:R1310-R1315
Kawaji T, Ando Y, Ando E, Sandgren O, Suhr OB, Tanihara H (2010a) Transthyretin-related vitreous amyloidosis in different endemic areas. Amyloid 17:105–108
Kawaji T, Ando Y, Hara R, Tanihara H (2010b) Novel therapy for transthyretin—related ocular amyloidosis. A pilot study of retinal laser photocoagulation. Ophthalmology 117:552–555
Keetch CA, Bromely EH, McCammon MG, Wang N, Christodoulou J, Robinson CV (2005) L55P transthyretin accelerates subunit exchange and leads to rapid formation of hybrid tetramers. J Biol Chem 280:41667–41674
Kelly JW (1998) The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 8:101–106
Klabunde T, Petrassi HM, Oza VB, Raman P, Kelly JW, Sacchettin JC (2000) Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol 7:312–321
Kohno K, Palha JA, Miyakawa K, Saraiva MJM, Ito S, Mabuchi T, Blaner WS, Iijima H, Tsukahara S, Episkopou V, Gottesman ME, Shimada K, Takahashi K, Yamamura K, Maeda S (1997) Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am J Pathol 150:1497–1508
Koike H, Misu K, Ikeda S, Ando Y, Nakazato M, Ando E, Yamamoto M, Hattori N, Sobue G, For the Study Group for Hereditary Neuropathy in Japan (2002) Type I (Transthyretin Met30) familial amyloid polyneuropathy in Japan. Early- vs late-onset form. Arch Neurol 59:1771–1776
Koike H, Misu K, Sugiura M, Iijima M, Mori K, Yamamoto M, Hattori N, Mukai E, Ando Y, Ikeda S, Sobue G (2004) Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 63:129–138
Koike H, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Tanaka F, Sobue G (2011) Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid 18:53–62
Kugimiya T, Jono H, Saito S, Maruyama T, Kadowaki D, Misumi Y, Hoshii Y, Tasaki M, Su Y, Ueda M, Obayashi K, Shono M, Otagiri M, Ando Y (2011) Loss of functional albumin triggers acceleration of transthyretin amyloid fibril formation in familial amyloidotic polyneuropathy. Lab Invest 91:1219–1228
Lai Z, Colon W, Kelly JW (1996) The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 35:6470–6482
Lai Z, McCulloch J, Lashuel HA, Kelly JW (1997) Guanidine hydrochloride-induced denaturation and refolding of transthyretin exhibits a marked hysteresis: equilibria with high kinetic barriers. Biochemistry 36:10230–10239
Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM (1997) Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272:17810–17814
Larsen PR (1972) Salicylate-induced increases in free triiodothyronine in human serum. Evidence of inhibition of triiodothyronine binding to thyroxine-binding prealbumin. J Clin Invest 51:1125–1134
Lashuel HA, Lai Z, Kelly JW (1998) Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. Biochemistry 37:17851–17864
Lashuel HA, Wurth C, Woo L, Kelly JW (1999) The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry 38:13560–13573
Lee KW, Lee DH, Son H, Kim YS, Park JY, Roh GS, Kim HJ, Kang SS, Cho GJ, Choi WS (2009) Clusterin regulates transthyretin amyloidosis. Biochem Biophys Res Commun 388:256–260
Lei M, Yanga M, Huo S (2004) Intrinsic versus mutation dependent instability/flexibility: a comparative analysis of the structure and dynamics of wild-type transthyretin and its pathogenic variants. J Struct Biol 148:153–168
Li X, Masliah E, Reixach N, Buxbaum JN (2011) Neuronal production of transthyretin in human and murine Alzheimer’s disease: is it protective? J Neurosci 31:12483–12490
Liepnieks JJ, Zhang LQ, Benson MD (2010) Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology 75:324–327
Liu L, Murphy RM (2006) Kinetics of inhibition of beta-amyloid aggregation by transthyretin. Biochemistry 45:15702–15709
Lyon AW, Narindrasorasak S, Young ID, Anastassiades T, Couchman JR, McCarthy KJ, Kisilevsky R (1991) Co-deposition of basement membrane components during the induction of murine splenic AA amyloid. Lab Invest 64:785–90
Macedo B, Batista AR, Ferreira N, Almeida MR, Saraiva MJ (2008) Anti-apoptotic reatment reduces transthyretin deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Biochim Biophys Acta 1782:517–22
Macedo B, Magalhães J, Batista AR, Maria João Saraiva MJ (2010) Carvedilol treatment reduces transthyretin deposition in a familial amyloidotic polyneuropathy mouse model. Pharmacol Res 62:514–522
Magalhães J, Santos SD, Saraiva MJ (2010) αB-crystallin (HspB5) in familial amyloidotic polyneuropathy. Int J Exp Pathol 91:515–521
Makover A, Moriwaki H, Ramakrishnan R, Saraiva MJM, Blaner WS, Goodman DS (1988) Plasma transthyretin. Tissue sites of degradation and turnover in the rat. J Biol Chem 263:8598–8603
Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82:4245–4249
Mathew V, Olson LJ, Gertz MA, Hayes DL (1997) Symptomatic conduction system disease in cardiac amyloidosis. Am J Cardiol 80:1491–1492
Matsubara K, Mizuguchi M, Igarashi K, Shinohara Y, Takeuchi M, Matsuura A, Saitoh T, Mori Y, Shinoda H, Kawano K (2005) Dimeric transthyretin variant assembles into spherical neurotoxins. Biochemistry 44:3280–3288
McCutchen SL, Colon W, Kelly LW (1993) Transthyretin mutation Leu55-Pro significantly alters tetramer stability and increases amyloidgenicity. Biochemistry 32:12119–12127
Miller SR, Sekijima Y, Kelly JW (2004) Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 84:545–552
Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, Kelly JW (1996) Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci USA 93:15051–15056
Misu K, Hattori N, Nagamatsu M, Ikeda S, Ando Y, Nakazato M, Takei Y, Hanyu N, Usui Y, Tanaka F, Harada T, Inukai A, Hashizume Y, Sobue G (1999) Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain 122:1951–1962
Misumi Y, Ando Y, Ueda M, Obayashi K, Jono H, Su Y, Yamashita T, Uchino M (2009) Chain reaction of amyloid fibril formation with induction of basement membrane in familial amyloidotic polyneuropathy. J Pathol 219:481–490
Misumi Y, Ueda M, Obayashi K, Jono H, Su Y, Yamashita T, Ohshima T, Ando Y, Uchino M (2012) Relationship between amyloid deposition and intracellular structural changes in familial amyloidotic polyneuropathy. Hum Pathol 43:96–104
Mita S, Maeda S, Shimada K, Araki S (1984) Cloning and sequence analysis of cDNA for human prealbumin. Biochem Biophys Res Commun 124:558–564
Mitsuhashi S, Yazaki M, Tokuda T, Yamamoto K, Ikeda S (2004) MRI analysis on a patient with the V30M mutation is characteristic of leptomeningeal amyloid. Amyloid 11:265–267
Miyata M, Sato T, Mizuguchi M, Nakamura T, Ikemizu S, Nabeshima Y, Susuki S, Suwa Y, Morioka H, Ando Y, Suico MA, Shuto T, Koga T, Yamagata Y, Kai H (2010) Role of the glutamic acid 54 residue in transthyretin stability and thyroxine binding. Biochemistry 49:114–123
Monteiro FA, Sousa MM, Cardoso I, Barbas do Amaral J, Guimarães A, Saraiva MJ (2006) Activation of ERK1/2 MAP kinases in familial amyloidotic polyneuropathy. J Neurochem 97:151–161
Murakami T, Yi S, Maeda S, Tashiro F, Yamamura K, Takahashi K, Shimada K, Araki S (1992) Effect of serum amyloid P component level on transthyretin-derived amyloid deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Am J Pathol 141:451–456
Murakami T, Ohsawa Y, Sunada Y (2008) The transthyretin gene is expressed in human and rodent dorsal root ganglia. Neurosci Lett 436:335–339
Murakami T, Ohsawa Y, Zhenghua L, Yamamura K, Sunada Y (2010) The transthyretin gene is expressed in Schwann cells of peripheral nerves. Brain Res 1348:222–225
Nagasaka T, Togashi S, Watanabe H, Iida H, Nagasaka K, Nakamura Y, Miwa M, Kobayashi F, Shindo K, Shiozawa Z (2009) Clinical and histopathological features of progressive-type familial amyloidotic polyneuropathy with TTR Lys54. J Neurol Sci 276:88–94
Nagata Y, Tashiro F, Yi S, Murakami T, Maeda S, Takahashi K, Shimada K, Okamura H, Yamamura K (1995) A 6-kb upstream region of the human transthyretin gene can direct developmental, tissue-specific, and quantitatively normal expression in transgenic mouse. J Biochem 117:169–175
Nakamura M, Ando Y (2004) Applications of gene therapy for familial amyloidotic polyneuropathy. Expert Opin Biol Th 4:1621–1627
Nakamura Y, Yutani C, Nakazato M, Date Y, Baba T, Goto Y (1999) A case of hereditary amyloidosis transthyretin variant Met30 with amyloid cardiomyopathy, less polyneuropathy, and the presence of giant cells. Pathol Int 49:898–902
Nakamura M, Ando Y, Nagahara S, Sano A, Ochiya T, Maeda S, Kawaji T, Ogawa M, Hirata A, Terazaki H, Haraoka K, Tanihara H, Ueda M, Uchino M, Yamamura K (2004) Targeted conversion of the transthyretin gene in vitro and in vivo. Gene Ther 11:838–846
Nakanishi T, Yoshioka M, Moriuchi K, Yamamoto D, Tsuji M, Takubo T (2010) S-sulfonation of transthyretin is an important trigger step in the formation of transthyretin-related amyloid fibril. Biochim Biophys Acta 1804:1449–1456
Nakazato M, Tanaka M, Matsukura S, Kangawa K, Matsuo H (1989) Quantitative analysis of amyloid fibril protein in systemic organs of patients with familial amyloidotic polyneuropathy. J Neurol Sci 89:235–242
Nakazato M, Shiomi K, Miyazato M, Matsukura S (1992) Type I familial amyloidotic polyneuropathy in Japan. Intern Med 31:1335–1338
Nichols WC, Padilla L-M, Benson MD (1989a) Prenatal detection of a gene for hereditary amyloidosis. Am J Med Genet 34:520–524
Nichols WC, Liepnieks JJ, McKusick VA, Benson MD (1989b) Direct sequencing of the gene for Maryland/German familial amyloidotic polyneuropathy type II and genotyping by allele-specific enzymatic amplification. Genomics 5:535–540
Noguchi H, Ohta M, Wakasugi S, Noguchi K, Nakamura H, Nakamura O, Miyakawa K, Takeya M, Suzuki M, Nagata N, Urano T, Oon T, Yamamura K (2002) Effect of the intestinal flora on amyloid deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Exp Anim 51:309–316
Ohya Y, Jono, H, Nakamura M, Hayashida S, Ueda M, Obayashi K, Misumi S, Asonuma K, Ando Y, Inomata Y (2010) Effect of recipient-derived cells on the progression of familial amyloidotic polyneuropathy after liver transplantation: a retrospective study. Ann Clin Biochem 47:529–534
Olofsson B-O, Grankvist K, Boman K, Forsberg K, Lafvas I, Lithner F (1989) Assessment of thyroid anad adrenal function in patients with familial amyloidotic polyneuropathy. J Intern Med 225:337–341
Olofsson B-O, Grankvist K, Olsson T, Boman K, Forsberg K, Lafvas I, Lithner F (1991) Assessment of hypothalamic-pituitary function in patients with familial amyloidotic polyneuropathy. J Intern Med 229:55–59
Olofsson B-O, Backman C, Karp K, Suhr OB (2002) Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation 73:745–751
Palmieri L de C, Lima LM, Freire JB, Bleicher L, Polikarpov I, Almeida FC, Foguel D (2010) Novel Zn2+ -binding sites in human transthyretin: implications for amyloidogenesis and retinol-binding protein recognition. J Biol Chem 285:31731–31741
Pepys MB, Rademachero TW, Amatayakul-Chantler S, Williams P, Noble GE, Hutchinson WL, Hawkins PN, Nelson SR, Gallimore JR, Herbert J, Hutton T, Dwek RA (1994) Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Nat Acad Sci USA 91:5602–5606
Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99 m Tc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46:1076–1084
Perugini E, Rappezi C, Piva T, Leone O, Bacchi-Reggiani L, Riva L, Salvi F, Lovato L, Branzi A, Fattori R (2006) Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 92:343–349
Petersen RB, Goren H, Cohen M, Richardson SL, Tresser N, Lynn A, Gali M, Estes M, Gambetti P (1997) Transthyretin amyloidosis: a new mutation associated with dementia. Ann Neurol 41:307–313
Pfeffer BA, Becerra SP, Borst DE, Wong P (2004) Expression of transthyretin and retinol binding protein mRNAs and secretion of transthyretin by cultured monkey retinal pigment epithelium. Mol Vis 10:23–30
Planté-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D, Said G (2007) Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 69:693–698
Pomfret E, Lewis WD, Jenkins R, Bergethon P, Dubrey Simon W, Reisinger J, Falk R, Skinner M,(1998) Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy. Transplantation 65:918–925
Powers ET, Powers DL (2008) Mechanisms of protein fibril formation: nucleated polymerization with competing off-pathway aggregation. Biophys J 94:379–391
Pras M, Prelli F, Franklin EC, Frangione B (1983) Primary structure of an amyloid prealbumin variant in familial polyneuropathy of Jewish origin. Proc Natl Acad Sci USA 80:539–542
Prashantha DK, Taly AB, Sinha S, Yasha TC, Gayathri N, Kovur J, Vijayan J (2010) Familial amyloidotic polyneuropathy with muscle, vitreous, leptomeningeal, and cardiac involvement: Phenotypic, pathological, and MRI description. Ann Indian Acad Neurol 13:142–144
Prelli F, Pras M, Frangione B (1985) The primary structure of human tissue amyloid P component from a patient with primary idiopathic amyloidosis. J Biol Chem 280:12895–12898
Pröpsting MJ, Kubicka S, Genschel J, Manns MP, Lochs H, Schmidt HH-J (2000) Inhibition of transthyretin-met30 expression using inosine15.1-hammerhead ribozymes in cell culture. Biochem Biophys Res Comm 279:970–973
Quintas A, Saraiva MJ, Brito RM (1997) The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. FEBS Lett 418:297–300
Quintas A, Saraiva MJ, Brito RM (1999) The tetrameric protein transthyretin dissociates to a non-native monomer in solution. A novel model for amyloidogenesis. J Biol Chem 74:32943–32949
Quintas A, Vaz DC, Cardoso I, Saraiva MJM, Brito RMM (2001) Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem 276:27207–27213
Raz A, Goodman DS (1969) The interaction of thyroxine with human plasma prealbumin and with the prealbumin-retinal-binding protein complex. J Biol Chem 244:3230–3237
Redondo C, Damas AM, Olofsson A, Lundgren E, Saraiva MJ (2000a) Search for intermediate structures in transthyretin fibrillogenesis: soluble tetrameric Tyr78Phe TTR expresses a specific epitope present only in amyloid fibrils. J Mol Biol 304:461–470
Redondo C, Damas AM, Saraiva MJ (2000b) Designing transthyretin mutants affecting tetrameric structure: implications in amyloidogenicity. Biochem J 348(Pt1):167–172
Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN (2004) Tissue damage in the amyloidoses: transthyretin monomers and non-native oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA 101:2817–2822
Reixach N, Adamski-Werner SL, Kelly JW, Koziol J, Buxbaum JN (2006) Cell based screening of inhibitors of transthyretin aggregation. Biochem Biophys Res Commun 348:889–897
Reixach N, Foss TR, Santelli E, Pascual J, Kelly JW, Buxbaum JN (2008) Human-murine transthyretin heterotetramers are kinetically stable and non-amyloidogenic. A lesson in the generation of transgenic models of diseases involving oligomeric proteins. J Biol Chem 283:2098–2107
Riboldi G, Del Bo R, Ranieri M, Magri F, Sciacco M, Moggio M, Bresolin N, Corti S, Comi GP (2011) Tyr78Phe transthyretin mutation with predominant motor neuropathy as the initial presentation. Case Rep Neurol 3:62–68
Richardson SJ, Lemkine GF, Alfama G, Hassani Z, Demeneix BA (2007) Cell division and apoptosis in the adult neural stem cell niche are differentially affected in transthyretin null mice. Neurosci Lett 421:234–238
Said G (2003) Familial amyloid polyneuropathy: mechanisms leading to nerve degeneration. Amyloid 10(Suppl. 1):7–12
Said G, Ropert A, Faux N (1984) Length-dependent degeneration of fibers in Portuguese amyloid poly neuropathy: a clinicopathologic study. Neurology 34:1025–1032
Sakashita N, Ando Y, Jinnouchi K, Yoshimatsu M, Terazaki H, Obayashi K, Takeya M (2001) Familial amyloidotic polyneuropathy (ATTR Val30Met) with widespread cerebral amyloid angiopathy and lethal cerebral hemorrhage. Pathol Int 51:476–480
Saraiva MJM (2001) Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum Mutat 17:493–503
Saraiva MJ, Costa PP, Goodman DS (1983) Studies on plasma transthyretin (prealbumin) in familial amyloidotic polyneuropathy, Portuguese type. J Lab Clin Med 102:590–603
Saraiva MJ, Birken S, Costa PP, Goodman DS (1984) Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest 74:104–119
Saraiva MJ, Sherman W, Marboe C, Figueira A, Costa P, de Freitas AF, Gawinowicz MA (1990) Cardiac amyloidosis: report of a patient heterozygous for the transthyretin isoleucine 122 variant. Scand J Immunol 32:341–346
Sasaki H, Yoshioka N, Takagi Y, Sakaki Y (1985) Structure of the chromosomal gene for human serum prealbumin. Gene 37:191–197
Sato T, Ando Y, Susuki S, Mikami F, Ikemizu S, Nakamura M, Suhr O, Anraku M, Kai T, Suico MA, Shuto T, Mizuguchi M, Yamagata Y, Kai H (2006) Chromium (III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation. FEBS Lett 580:491–496
Sawabe M, Hamamatsu A, Ito T, Arai T, Ishikawa K, Chida K, Izumiyama N, Honma N, Takubo K, Nakazato M (2003) Early pathogenesis of cardiac amyloid deposition in senile systemic amyloidosis: close relationship between amyloid deposits and the basement membranes of myocardial cells. Virchows Arch 442:252–257
Schneider F, Hammarström P, Kelly JW (2001) Transthyretin slowly exchanges subunits under physiological conditions: a convenient chromatographic method to study subunit exchange in oligomeric proteins. Protein Sci 10:1606–1613
Schormann N, Murrell JR, Benson MD (1998) Tertiary structures of amyloidogenic and non-amyloidogenic transthyretin variants: new model for amyloid fibril formation. Amyloid 5:175–187
Schreiber G, Aldred AR, Jaworowski A, Nilsson C, Achen MG, Segal MB (1990) Thyroxine transport from blood to brain via transthyretin synthesis in choroid plexus. Am J Physiol 258:R338–R345
Schwarzman AL, Tsiper M, Wente H, Wang A, Vitek MP, Vasiliev V, Goldgaber D (2004) Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants. Amyloid 11:1–9
Sebastião MP, Saraiva NJ, Damas AM (1998) The crystal structure of amyloidogenic Leu55Pro transthyretin variant reveals a possible pathway for transthyretin polymerization into amyloid fibrils. J Biol Chem 273:24715–24722
Sebastião MP, Merlini G, Saraiva MJ, Damas AM (2000) The molecular interaction of 4’-iodo-4’-deoxydoxorubicin with Leu-55Pro transthyretin ‘amyloid-like’ oligomer leading to disaggregation. Biochem J 351:273–279
Sekijima Y, Hammarström P, Matsumura M, Shimizu Y, Iwata M, Tokuda T, Ikeda S, Kelly JW (2003) Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. Lab Invest 83:409–417
Sekijima Y, Wiseman RL, Balch WE, Kelly JW (2005) The biological and chemical basis for tissue-selective amyloid disease. Cell 121:73–85
Sekijima Y, Kelly JW, Ikeda S (2008) Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des 14:3219–3230
Editors
Sekijima Y, Yoshida K, Tokuda T, Ikeda S (2001) (Last updated 2012). Familial transthyretin amyloidosis. In: Pagon RA, Bird TD, Dolan CR et al (eds) GeneReviews (Internet). University of Washington, Seattle, 1993
Serga AA, Altenbach C, Gingery M, Hubbell WL, Yeates TO (2001) Identification of a subunit interface in transthyretin amyloid fibrils: evidence for self-assembly from oligomeric building blocks. Biochemistry 40:9089–9096
Serot JM, Christmann D, Dubost T, Couturier M (1997) Cerebrospinal fluid transthyretin: aging and late onset Alzheimer’s disease. J Neurol Neurosurg Psychiatry 63:506–508
Serpell LC, Sunde M, Fraser PE, Luther PK, Morris EP, Sangren O, Lundgren E, Blake CCF (1995) Examination of the structure of the transthyretin amyloid fibril by image reconstruction from electron micrographs. J Mol Biol 254:113–118
Shimojima Y, Morita H, Kobayashi S, Talei Y, Ikeda S (2008) Ten-year follow-up of peripheral nerve function in patients with familial amyloid polyneuropathy after liver transplantation. J Neurol 255:1220–1225
Shnyrov VL, Villar E, Zhadan GG, Sanchez-Ruiz JM, Quintas A, Saraiva MJ, Brito RM (2000) Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin. Biophys Chem 88:61–67
Simões CJV, Mukherjee T, Brito RMM, Jackson RM (2010) Toward the discovery of functional transthyretin amyloid inhibitors: application of virtual screening methods. J Chem Inf Model 50:1806–1820
Smeland S, Kolset SO, Lyon M, Kaare R, Norum KR, Blomhoff R (1997) Binding of perlecan to transthyretin in vitro. Biochem J 326:829–836
Soares ML, Coelho T, Sousa A, Batalov S, Conceição I, Sales-Luís ML, Ritchie MD, Williams SM, Nievergelt CM, Schork NJ, Saraiva MJ, Buxbaum JN (2005) Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease. Hum Mol Genet 14:543–553
Sobue G, Nakao N, Murakami K, Yasuda T, Sahashi K, Mitsuma T, Sasaki H, Sakaki Y, Takahashi A (1990) Type I familial amyloid polyneuropathy. A pathological study of the peripheral nervous system. Brain 113:903–919
Sousa MM, Saraiva MJ (2003) Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling. Prog Neurobiol 71:385–400
Sousa MM, Saraiva MJ (2008) Transthyretin is not expressed by dorsal root ganglia cells. Exp Neurol 214:362–365
Sousa MM, Cardoso I, Fernandes R, Guimaraes A, Saraiva MJ (2001a) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of non-fibrillar aggregates. Am J Pathol 159:1993–2000
Sousa MM, Du Yan S, Fernandes R, Guimarães A, Stern D, Saraiva MJ (2001b) Familial amyloid polyneuropathy: receptor for advanced glycation endproducts-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci 21:7576–7586
Sousa MM, Fernandes R, Palha JA, Taboada A, Vieira P, Saraiva MJ (2002) Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. Am J Pathol 161:1935–1948
Sousa MM, Ferrao J, Fernandes R, Guimaraes A, Geraldes JB, Perdigoto R, Tome L, Mota O, Negrao L, Furtado AL, Saraiva MJ (2004) Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers. Lab Invest 84:865–873
Sousa MM, Barbas do Amaral J, Guimarães A, Saraiva MJ (2005) Up-regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase-associated lipocalin and matrix metalloproteinase-9 in familial amyloid polyneuropathy. FASEB J 19:124–126
Skare J, Yazici H, Erken E, Debe H, Cohen A, Milunsky A, Skinner M (1990) Homozygosity for the met30 transthyretin gene in a Turkish kindred with familial amyloidotic polyneuropathy. Hum Genet 86:89–90
Snow CM, Senior A, Gerace L (1987) Monoclonal antibodies identify a group of nuclear pore complex glycoproteins. J Cell Biol 104:1143–1156
Stangou AJ, Hawkins PN (2004) Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol 17:615–620
Stangou AJ, Heaton ND, Hawkins PN (2005) Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med 352:2356
Steinrauf LK, Cao Y, Hamilton J, Murrell J, Liepnieks JJ, Benson MD (1991) Preparation and crystallization of human transthyretin (prealbumin) variants. Biochem Biophys Res Commun 179:804–809
Stockigt JR, Lim CF, Barlow JW, Wynne KN, Mohr VS, Topliss DJ, Hamblin PS, Sabto J (1985) Interaction of furosemide with serum thyroxine binding sites: in vivo and in vitro studies and comparison with other inhibitors. J Clin Endocrinol Metab 60:1025–1031
Subasinghe S, Unabia S, Barrow CJ, Mok SS, Aguilar MI, Small DH (2003) Cholesterol is necessary both for the toxic effect of Abeta peptides on vascular smooth muscle cells and for Abeta binding to vascular smooth muscle cell membranes. J Neurochem 84:471–479
Suhr OB, Ericzon BG, Friman S (2002) Long-term follow-up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type). Liver Transplant 8:787–794
Suk JY, Zhang F, Balch WE, Linhardt RJ, Kelly JW (2006) Heparin accelerates gelsolin amyloidogenesis. Biochemistry 45:2234–2242
Takahashi K, Yi S, Kimura Y, Araki S (1991) Familial amyloidotic polyneuropathy type 1 in Kumamoto, Japan: a clinicopathologic, histochemical, immunohistochemical, and ultrastructural study. Hum Pathol 21:519–527
Takaoka Y, Tashiro F, Yi S, Maeda S, Shimada K, Takahashi K, Sakaki Y, Yamamura K (1997) Comparison of amyloid deposition in two lines of transgenic mouse that model familial amyloidotic polyneuropathy, type I. Transgenic Res 6:261–269
Takei Y, Gono T, Yazaki M, Ikeda S, Ikegami T, Hashikura Y, Miyagawa S, Hoshii Y (2007) Transthyretin-derived amyloid deposition on the gastric mucosa in domino recipients of familial amyloid polyneuropathy liver. Liver Transplant 13:215–218
Tanaka K, Yamada T, Ohyagi Y, Asahara H, Horiuchi I, Kira J (2001) Suppression of transthyretin expression by ribozymes: a possible therapy for familial amyloidotic polyneuropathy. J Neurol Sci 183:79–84
Tanskanen M, Peuralinna T, Polvikoski T, Notkola I-L, Sulkava R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ, Myllykangas L (2008) Senile systemic amyloidosis affects 25 % of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 40:232–239
Tawara S, Nakazato M, Kangawa K, Matsuo H, Araki S (1983) Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type). Biochem Biophys Res Commun 116:880–888
Teng MH, Yin JY, Vidal R, Ghiso J, Kumar A, Rabenou R, Shah A, Jacobson DR, Tagoe C, Gallo G, Buxbaum J (2001) Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis. Lab Invest 81:385–396
Terry CJ, Damas AM, Oliveira P, Saraiva MJM, Alves IL, Costa PP, Matias PM, Sakaki Y, Blake CCF (1993) Structure of Met30 variant of transthyretin and its amyloidogenic implications. EMBO J 12:735–741
Thylén C, Wahlqvist J, Haettner E, Sandgren O, Holmgren G, Lundgren E (1993) Modifications of transthyretin in amyloid fibrils: analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation. EMBO J 12:743–748
Togashi S, Watanabe H, Nagasaka T, Shindo K, Shiozawa Z, Maeda S, Tawata M, Onaya T (1999) An aggressive familial amyloidotic polyneuropathy caused by a new variant transthyretin Lys54. Neurology 53:637–639
Tojo K, Sekijima Y, Kelly JW, Ikeda S (2006) Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res 56:441–449
Toyooka K, Fujimura H, Ueno S, Yoshikawa H, Kaido M, Nishimura T, Yorifuji S, Yanagihara T (1995) Familial amyloid polyneuropathy associated with transthyretin Gly42 mutation: a quantitative light and electron microscopic study of the peripheral nervous system. Acta Neuropathol 90:516–525
Tsuzuki T, Mita S, Maeda S, Araki S, Shimada K (1985) Structure of the human prealbumin gene. J Biol Chem 260:12224–12227
Ueda M, Misumi Y, Mizuguchi M, Nakamura M, Yamashita T, Sekijima Y, Ota K, Shinriki S, Jono H, Ikeda S, Suhr OB, Ando Y (2009) SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy. Clin Chem 55:1223–1227
Ueda M, Horibata Y, Shono M, Misumi Y, Oshima T, Su Y, Tasaki M, Shinriki S, Kawahara S, Jono H, Obayashi K, Ogawa H, Ando Y (2011) Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study. Mod Pathol 24:1533–1544 (electronical form)
Uemichi T, Murrell JR, Zeldenrust S, Benson MD (1992) A new mutant transthyretin (Arg 10) associated with familial amyloid polyneuropathy. J Med Genet 29:888–891
Uemichi T, Liepnieks JJ, Benson MD (1997) A trinucleotide deletion in the transthyretin gene (AV122) in a kindred with familial amyloidotic polyneuropathy. Neurology 48:1667–1670
Uemichi T, Uitti RJ, Koeppen AH, Donat JR, Benson MD (1999) Oculoleptomeningeal amyloidosis associated with a new transthyretin variant Ser64. Arch Neurol 56:1152–1155
Vital C, Vital A, Bouillot-Eimer S, Brechenmacher C, Ferrer X, Lagueny A (2004) Amyloid neuropathy: a retrospective study of 35 peripheral nerve biopsies. J Peripher Nerv Syst 9:232–241
Wakasugi S, Inomoto T, Yi S, Naito M, Uehira M, Iwanaga T, Maeda S, Araki K, Miyazaki J, Takahashi K, Shimada K, Yamamura K (1987) A transgenic mouse model of familial amyloidotic polyneuropathy. Proc Jpn Acad 63(B):344–347
Wallace MR, Naylor SL, Kluve-Beckerman B, Long GL, Mc-Donald L, Shows TB, Benson MD (1985) Localization of the human prealbumin gene to chromosome 18. Biochem Biophys Res Commun 129:753–758
Wallace MR, Dwulet FE, Conneally PM, Benson MD (1986) Biochemical and molecular genetic characteristics of a new variant prealbumin associated with hereditary amyloidosis. J Clin Invest 78:6–12
Wallace MR, Conneally PM, Benson MD (1988) A DNA test for Indiana/Swiss hereditary amyloidosis (FAP II). Am J Hum Genet 43:182–187
Westermark P, Johansson B, Natvig JB (1979) Senile cardiac amyloidosis: evidence of two different amyloid substances in the ageing heart. Scand. J Immunol 10:303–308
Westermark P, Sletten K, Johansson B, Cornwell GG 3rd (1990) Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 87:2843–2845
White JT, Kelly JW (2001) Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro. Proc Natl Acad Sci USA 98:13019–13024
Whitehead AS, Skinner M, Bruns GA, Costello W, Edge MD, Cohen AS, Sipe JD (1984) Cloning of human prealbumin complementary DNA. Localization of the gene to chromosome 18 and detection of a variant prealbumin allele in a family with familial amyloid polyneuropathy. Mol Biol Med 2:411–423
Wojtczak A, Cody V, Luft JR, Pangborn W (1996) Structures of human transthyretin complexed with thyroxine at 2.0 Å resolution and 3’,5’-dinitro-N-acetyl-L-thyronine at 2.2 Å resolution. Acta Crystallogr D 52:758–765
Yamada M, Hatakeyama S, Tsukagoshi H (1984) Peripheral and autonomic nerve lesions in systemic amyloidosis. Three pathological types of amyloid polyneuropathy. Acta Pathol Jpn 34:1251–1266
Yamamura K, Wakasugi S, Maeda S, Inomoto T, Iwanaga T, Uehira M, Araki K, Miyazaki J, Shimada K (1987) Tissue-specific and developmental expression of human transthyretin gene in transgenic mice. Dev Genet 8:195–205
Yamashita T, Hamidi Asl K, Yazaki M, Benson MD (2005) A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. Amyloid 12:127–130
Yan C, Costa RH, Darnell JE Jr, Chen J, Van Dyke TA (1990) Distinct positive and negative elements control the limited hepatocyte and choroid plexus expression of transthyretin in transgenic mice. EMBO J 9:869–878
Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889–9897
Yang M, Lei M, Huo S (2003) Why is Leu55→Pro55 transthyretin variant the most amyloidogenic: insights from molecular dynamics simulations of transthyretin monomers. Protein Sci 12:1222–1231
Yazaki M, Tokuda T, Nakamura A, Higashikata T, Koyama J, Higuchi K, Harihara Y, Baba S, Kametani F, Ikeda S (2000) Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun 274:702–706
Yi S, Takahashi K, Naito M, Tashiro F, Wakasugi S, Maeda S, Shimada K, Yamamura K, Araki S (1991) Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met30) gene. Pathologic similarity to human familial amyloidotic polyneuropathy, Type I. Am J Patbol 138:403–412
Yoshimatsu S, Amdo Y, Terazaki H, Sakashita N, Tada S, Yamashita T, Suga M, Uchino M, Ando M (1998) Endoscopic and pathological manifestation of the gastrointestinal tract in familial amyloidotic polyneuropathy type I (Met30). J Intern Med 243:65–72
Yoshinaga T, Nakazato M, Ikeda S, Ohnishi A (1992) Homozygosity for the transthyretin-Met30 gene in three Japanese siblings with type I familial amyloidotic polyneuropathy. Neurology 42:2045–2047
Zhao G, Li Z, Araki K, Haruna K, Yamaguchi K, Araki M, Takeya M, Ando Y, Yamamura K (2008) Inconsistency between hepatic expression and serum concentration of transthyretin in mice humanized at the transthyretin locus. Genes Cells 13:1257–1268
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Nagasaka, T. (2012). Familial Amyloidotic Polyneuropathy and Transthyretin. In: Harris, J. (eds) Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease. Subcellular Biochemistry, vol 65. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-5416-4_21
Download citation
DOI: https://doi.org/10.1007/978-94-007-5416-4_21
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-5415-7
Online ISBN: 978-94-007-5416-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)